Vistagen Therapeutics Appoints New CFO and Discloses Executive Compensation Arrangements
Vistagen Therapeutics, Inc. (SEC file no. 0001411685) filed an 8-K on October 9, 2026, reporting appointment of new CFO and related compensatory arrangements under Item 5.02.
51CFO view：Item 5.02 filings require immediate SOX 302 certifications and full disclosure of employment agreements. For pre-IPO companies, this underscores that CFO candidates must have verifiable SEC signing authority history and documented experience leading ≥2 annual 10-K cycles.
Vistagen Therapeutics, Inc. (SEC file no. 0001411685) filed an 8-K on October 9, 2026, reporting appointment of new CFO and related compensatory arrangements under Item 5.02.
Source：SEC EDGAR · 8-K 重大事项公告
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
How is a US-listed CFO paid?
Base, equity incentive and listing-milestone bonus: structure and ranges.
Read →
Who owns SEC reporting and US GAAP?
Signature responsibility for 10-K / 10-Q / 8-K / 20-F, and common comments.
Read →
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →